{"entity":{"id":"kim-chi","kind":"person","name":"Kim N. Chi","aka":[],"tldr":"Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer.","summary":"Kim Chi was principal investigator of TITAN, which established apalutamide with androgen deprivation in metastatic hormone-sensitive prostate cancer, and of MAGNITUDE, which showed niraparib plus abiraterone benefits patients with HRR gene alterations. His group at the Vancouver Prostate Centre pioneered ctDNA profiling of androgen receptor alterations. He also co-led the CCTG PR.20 and PR.17 studies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chi%20KN%5BAuthor%5D%20prostate%20apalutamide%20OR%20niraparib"}],"tags":["prostate","trialist","canada"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["parp-inhibitor","liquid-biopsy"],"targets":["androgen-receptor","parp","brca"],"drugs":["niraparib","abiraterone"],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":["magnitude"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Chief Medical Officer, BC Cancer; Professor, University of British Columbia","institutionId":"bc-cancer","specialisms":["Prostate cancer","Androgen receptor inhibitors","PARP inhibitor combinations","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chi%20KN%5BAuthor%5D%20prostate%20apalutamide%20OR%20niraparib"}],"papers":[{"title":"Apalutamide for metastatic, castration-sensitive prostate cancer (TITAN)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903307"},{"title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer (MAGNITUDE)","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.01649"}]},"route":"/people/kim-chi/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"institution":[{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/"}],"trial":[{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/"}]}}